Mark Avagliano is Chief Business Officer at G1 Therapeutics, Inc. (GTHX). They have made 4 open-market trades across 1 company since 2022, most recently 2024-09-18.
CIK 0001783503
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GTHX | 262,645 | $1.9M |
Shares reported on the most recent Form 4, priced at the 2024-09-18 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.